Synthesis and structure-activity relationships of new 1,3- disubstituted cyclohexanes as structurally rigid leukotriene B4 receptor antagonists

Journal of Medicinal Chemistry

Volumn 42, Issue 26, 1999, Pages 5289-5310

  Poudrel, Jean Marc ^a   Hullot, Pierre ^a   Vidal, Jean Pierre ^a   Girard, Jean Pierre ^a   Rossi, Jean Claude ^a   Muller, Agnès ^a   Bonne, Claude ^a   Bezuglov, Vladimir ^b   Serkov, Igor ^b   Renard, Pierre ^c   Pfeiffer, Bruno ^c  

^a UNIV MONTPELLIER   (France)

^b RUSSIAN ACADEMY OF SCIENCES   (Russian Federation)

^c ADIR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

2 [2 PROPYL 3 [3 [2 ETHYL 4 (4 FLUOROPHENYL) 5 HYDROXYPHENOXY]PROPOXY]PHENOXY]BENZOIC ACID; 7 [3 [2 CYCLOPROPYLMETHYL 3 METHOXY 4 [(METHYLAMINO)CARBONYL]PHENOXY]PROPOXY] 3,4 DIHYDRO 8 PROPYL 2H 1 BENZOPYRAN 2 PROPANOIC ACID; ALLYL COMPOUND; CARBOXYLIC ACID; CYCLOHEXANE DERIVATIVE; LEUKOTRIENE B4 RECEPTOR ANTAGONIST; MOXILUBANT MALEATE;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EDEMA; MALE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; CYCLOHEXANES; GUINEA PIGS; HUMANS; LEUKOTRIENE B4; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; NEUTROPHILS; PROTEIN BINDING; RECEPTORS, LEUKOTRIENE B4; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033620014     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9910573     Document Type: Article

References (95)

1. (a) Bray, M. A. Leukotrienes in Inflammation. Agents Actions 1986, 19, 87-99.
2. (b) Brain, S. D.; Williams, T. J. Leukotrienes and Inflammation. Pharm. Ther. 1990, 46, 57-66.
3. 4 in Inflammation. Crit. Rev. Immunol. 1990, 10, 1-12.
4. 4 is a Potent Stereospecific Stimulator of Neutrophil Chemotaxis and Adherence. Blood 1981, 58, 658-661.
5. (b) Ringertz, B.; Palmblad, J.; Radmark, O.; Malmsten, C. Leukotriene-Induced Neutrophil Aggregation In Vitro. FEBS Lett. 1982, 147, 180-182.
6. 4. J. Pharm. Pharmacol. 1981, 33, 616-617.
7. 4 and the Role of Polymorphonuclear Leukocytes. Inflammation 1982, 6, 189-199.
8. 4-Like Material in Scale of Psoriatic Skin Lesions. Br. J. Pharmacol. 1984, 83, 313-317.
9. 4 but not 12-Hydroxy-Eicosatetraenoic acid, is Present in Biologically Active Amounts in Acute Guttate Lesions. J. Invest. Dermatol. 1989, 92, 837-841.
10. 4 by Colonic Mucosa in Inflammatory Bowel Disease. Gastroenterology 1984, 86, 453-460.
11. (d) Klickstein, L. B.; Shapleigh, L.; Goetzl, E. Lipoxygenation of Arachidonic Acid as a Source of Polymorphonuclear Leukocyte Chemotactic Factors in Synovial Fluid and Tissue in Rheumatoid Arthritis and Spondylosing Arthritis. J. Clin. Invest. 1980, 66, 1166-1170.
12. 4, a mediator of Inflammation present in Synovial Fluid in Rheumatoid Arthritis. Ann. Rheum. Dis. 1983, 42, 677-679.
13. 4 and Immunological Parameters in Rheumatoid Synovial Fluids. Inflammation 1991, 15, 497-503.
14. 4, an Inflammatory Mediator in Gout. Lancet 1982, 2, 1122-1124.
15. 4. Lancet 1993, 342, 465-469.
16. 4 is Markedly Elevated in Epithelial Lining Fluid of Patients with Cystic Fibrosis. Am. Rev. Respir. Dis. 1993, 48, 896-901.
17. 4 Levels in Patients with Obstructive Pulmonary Disease. Chest 1991, 99, 289-291.
18. 4 in Bronchoalveolar Lavage in Bronchial Asthma and Other Respiratory Diseases. J. Allergy Clin. Immunol. 1989, 84, 19-26.
19. 4 and of their Isomers in Arterial, Mixed Venous Blood and Bronchoalveolar Lavage Fluid of Patients with Cystic Fibrosis. Intensive Care Med. 1989, 15, 298-301.
20. 4 Pathway to Inflammation Control. Nature 1996, 384, 39-43.
21. 4 to Receptors on Human Polymorphonuclear Leukocytes. J. Immunol. 1982, 129, 1600-1604.
22. 4Binding to Human Neutrophils. Prostaglandins 1984, 28, 837-849.
23. 4, that Mediates Chemotaxis. Nature 1997, 387, 620-624.
24. th Meeting of the Federation of European Biochemical Societies FEBS'99, Nice. Abstr. Biochimie 1999, Suppl 6, s143.
25. 4. Identification of a Subset of High Affinity Affinity Receptors that Transduce the Chemotactic Response. J. Exp. Med. 1984, 159, 1027-1041.
26. 4-calcium complexes. Proc. Natl. Acad. Sci. U.S.A. 1984, 81, 3370-3374.
27. 4 in Solution Based on High-Field Nuclear Magnetic Resonance Measurements. J. Am. Chem. Soc. 1984, 106, 4021-4025.
28. 4 Receptor Antagonists. Bioorg. Med. Chem. Lett. 1996, 6, 2349-2354.
29. 4 and their Receptor Binding Activity. Bioorg. Med. Chem. 1997, 5, 1621-1647.
30. 4 Receptor Agonist/Antagonist Activities of SC-45694 in Human Neutrophils. J. Pharmacol. Exp. Ther. 1994, 268, 1493-1498.
31. 4 Analogue, J. Chem. Soc., Perkin Trans. 1989, 2133-2134.
32. 4 Receptor Antagonists. In The 7th International Conference on Prostaglandins and Related Compounds; Florence (Italy), 1990; p 303.
33. 4. Tetrahedron Lett. 1988, 29, 143-146.
34. 4 Analogues: Inhibition of Guinea Pig Eosinophil Migration In Vitro by the 2,6-Disubstituted Pyridine Analogues U-75,302 and U-75,485. Prostaglandins 1991, 42, 211-224.
35. 4 and their Receptor Binding Activity. J. Med. Chem. 1993, 36, 3308-3320.
36. (h) Miyashiro, J. M.; Haack, R. A.; Djuric, S. W. In Abstracts of Papers,198th National Meeting of the American Chemical Society, Miami Beach, 1989; American Chemical Society: Washington, DC, 1989; MEDI 54.
37. 4 Receptor Antagonist and its Effect on Neutrophil, Eosinophil and Monocyte Functions. The American Academy of Allergy and Immunology, 48th Annual Meeting, Orlando, Florida, March 6-11, 1992. In J. Allergy Clin. Immunol. 1992, 89, 236.
38. (a) Brooks, C. D. W.; Summers, J. B. Modulators of Leukotriene Biosynthesis and Receptor Activation. J. Med. Chem. 1996, 39, 2629-2654.
39. 4 Receptor Antagonist Research. Exp. Opin. Ther. Pat. 1996, 6, 21-28.
40. (c) Higa, A.; Eto, T.; Nawa, Y. Evaluation of the Role of Neutrophils in the Pathogenesis of Acetic Acid-Induced Colitis in Mice. Scand J. Gastroenterol. 1997, 32, 564-568.
41. 4 Receptor Antagonist (LY293111). Biochem. Pharmacol. 1997, 53, 1005-1012.
42. 4 Receptor Antagonist in the Treatment of Stable Plaque Psoriasis. Br. J. Dermatol. 1998, 139, 396-402.
43. 4) Receptor. Bioorg. Med. Chem. Lett. 1997, 7, 2307-2312
44. 4 Receptor Antagonist with Oral Antiinflammatory Activity. J. Med. Chem. 1996, 39, 3837-3841.
45. 4 Receptor Antagonists: Recent Clinical Developmens, Expert. Opin. Invest. Drugs 1996, 5, 73-77.
46. 4 derivatives. Ger. Offen. DE 4,227,790; 1994.
47. 4 derivatives, process for their preparation, and their use as drugs. Ger. Offen. DE 4,236-540; 1994.
48. 4 derivatives as drugs. Ger. Offen. DE 4,242-390; 1994.
49. 2CuLi Which Allow Selective Group Transfer. J. Am. Chem. Soc. 1972, 94, 7210-7211.
50. 2 (dl), J. Am. Chem. Soc. 1969, 91, 5675-5677.
51. 2 (dl) via a Tricarboxylic Intermediate, Tetrahedron Lett. 1970, 307-310.
52. 1. J. Org. Chem. 1972, 37, 2921-2922.
53. (e) Cowherd, F. G.; Doria, M. C.; Galeazzi, E.; Muchowski, J. M. N-Nitromethylphthalimide. A Formyl Anion Equivalent. Can. J. Chem. 1977, 55, 2919-2929.
54. 2 Methyl Ester. J. Org. Chem. 1986, 50, 4762-4766.
55. 4 Receptor Antagonist Sodium (1S*, 3S*)-1-Hydroxy-3-[(3R*S*,E)-3-hydroxy-7-phenyl-1-hepten-1-yll- 1-cyclohexane Acetate. Arzneim. Forsch./Drug Res. 1997, 47, 51-58.
56. Corey, E. J.; Floyd, D.; Lipshutz, B. H. (3-methyl-3-methoxy-1-butynyl) copper, an Useful Reagent for the Generation of Mixed Cuprates. J. Org. Chem. 1978, 43, 3418-3420.
57. (a) Corey, E. J.; Raju, N. A New General Synthetic Route to Bridged Ortho esters, Tetrahedron Lett. 1983, 24, 5571-5574.
58. (b) Bannai, K.; Tanaka, T.; Okamura, N.; Hazato, A.; Sugiura, S.; Manabe, K.; Tomimori, K.; Kurozumi, S. Improved Synthesis of Isocarbacyclin Using Regioselective Alkylation of Allylic Alcohols. Tetrahedron Lett. 1986, 27, 6353-6356.
59. (c) Kugel, C.; Lellouche, J. P.; Beaucourt, J. P.; Niel, G.; Girard, J. P.; Rossi, J. C. Stereospecific Total Synthesis of (5,6)-DiHETE isomers. Tetrahedron Lett. 1989, 30, 4947-4950.
60. Takacs, J. M.; Helle, M. A.; Seely, F. L. An Improved Procedure for the Two Carbon Homologation of Esters to α,/β-Unsaturated Esters, Tetrahedron Lett. 1986, 27, 1257-1260
61. (a) Savignac, P.; Mathey, F. Une Voie Simple et Efficace d'Accés aux β-cétophosphonates. Tetrahedron Lett. 1976, 33, 2829-2832.
62. 4. Tetrahedron Lett. 1990, 31, 4131-4134.
63. (a) Maillard, J.; Delaunay, P.; Langlois, M.; Portevin, B.; Legeai, J.; Benharkate, M. Synthèse de Dérivés Aminés du Tétrahydro-4,5,6,7 Benzotriazole. Eur. J. Med. Chem.-Chim. Ther. 1984, 19, 457-460.
64. (b) House, H. O.; Latham, R. A.; Slater, C. D. Preparation of 3-Isoprenylcyclohexanone. J. Org. Chem. 1966, 31, 2667-2669.
65. Gemal, A. L.; Luche, J. L. Lanthanoids in Organic Synthesis. 6. The Reduction of α-Enones by Sodium Borohydride in the Presence of Lanthanoid Chlorides: Synthetic and Mechanistic Aspects. J. Am. Chem. Soc. 1981, 103, 5454-5459.
66. Huet, F.; Lechevallier, A.; Pellet, M.; Conia, J. M. Wet Silica Gel; A convenient Reagent for Deacetalization. Synthesis 1978, 63-65
67. Wadsworth, W. S.; Emmons, W. D. Ethyl Cyclohexylideneacetate. Org. Synth. 1965, 45, 44-47.
68. Tay, M. K.; About-Jaudet, E.; Collignon, N.; Savignac, P. Phosphonates α-lithiés, Agents de Transfert Fonctionnel. Préparation de Phosphonates α-Amides et d'Amides β-insaturés, α-substitués, Tetrahedron 1989, 45, 4415-4430.
69. Ganem, B.; Small, V. R. Ferric Chloride in Acetic Anhydride. A Mild and Versatile Reagent for the Cleavage of Ethers. J. Org. Chem. 1974, 39, 3728-3730.
70. (a) Bezuglov, V. V.; Bergel'son, L. D. Synthesis of Prostaglandins. I 11-Fluoro and 15-Fluoro Prostaglandins. Soviet J. Bioorg. Chem. 1979, 5, 1137-1140.
71. (b) Gerstenberger, M. R. C.; Hass, A. Methods of Fluorination in Organic Chemistry. Angew. Chem., Int. Ed. Engl. 1981, 20, 647-667.
72. 4-Induced Lysozyme Release from Rat Polymorphonuclear Leukocytes. Prostaglandins 1990, 39, 459-467.
73. 4 and its Structural Analogues in Chemotactic, Lysosomal-Enzyme Release and Receptor-Binding Assays. Eur. J. Biochem. 1993, 218, 59-66.
74. 4 Receptor. Prostaglandins 1987, 33, 617-625.
75. 4 Receptor. In The 7th International Conference on Prostaglandins and Related Compounds; Florence (Italy), 1990; p 177.
76. 4 from Human Leukocytes. FEBS Lett. 1981, 130, 107-112.
77. 4 and its ω-Oxidized Metabolites. FEBS Lett. 1981, 136, 141-144.
78. 4 in Human Polymorphonuclear Leukocytes, J. Biol. Chem. 1984, 259, 10181-10187.
79. (a) Crossley, N. S. The Synthesis and Biological Activity of Potent, Selective Luteolytic Prostaglandins. Prostaglandins 1975, 10, 5-18.
80. (b) Resul, B.; Stjernschantz, J.; No, K.; Liljebris, C.; Selén, G.; Astin, M.; Karlsson, M.; Bito, L. Z. Phenyl-Substituted Prostaglandins: Potent and Selective Antiglaucoma Agents. J. Med. Chem. 1993, 36, 243-248.
81. 2α Isopropyl Ester: Potential Antiglaucoma Agents. J. Med. Chem. 1995, 38, 289-304.
82. 4 Receptor Antagonist. J. Med. Chem. 1992, 35, 4253-4255.
83. 4-Dimethylamide. Biochem. Biophys. Res. Commun. 1982, 106, 741-747.
84. 4 to Dihydro and Dihydro-oxo Products by Porcine Leukocytes. J. Biol. Chem. 1989, 264, 5364-5369.
85. 4 12-Hydroxydehydrogenase. J. Biol. Chem. 1993, 268, 18128-18135.
86. 4 12-Hydroxydehydrogenase. J. Biol. Chem. 1996, 271, 2844-2850.
87. 4 Receptor Antagonists. J. Med. Chem. 1994, 37, 3327-3336.
88. Goetzl, E.; Pickett, W. C. Novel Structural Determinants of the Human Neutrophil Chemotactic Activity of Leukotriene B. J. Exp. Med. 1981, 153, 482-487.
89. 4 Analogue Toward the Reductase Metabolism. Prostaglandins 1993, 45, 335-345.
90. Welch, J. T. Advances in the Preparation of Biologically Active Organofluorine Compounds. Tetrahedron 1987, 43, 3123-3197.
91. Boyum, A. Isolation of Mononuclear Cells and Granulocytes from Human Blood. Isolation of Mononuclear Cells by One Centrifugation, and of Granulocytes by Combining Centrifugation and Sedimentation at 1 g. Scand. J. Clin. Lav. Invest. 1968, 21, 77-89.
92. Muller, A.; Rechencq, E.; Kugel, C.; Lellouche, J. P.; Beaucourt, J. P.; Niel, G.; Girard, J. P.; Rossi, J. C.; Bonne, C. Comparative Biological Activities of the four Synthetic (5,6)-DiHETE Isomers. Prostaglandins 1989, 38, 635-644.
93. 4 to Endothelial Cell Membranes. Prostagland. Leuk. Med. 1987, 26, 233-240.
94. Gallin, J. Chromium-51 Radioimmunoassay for Chemotaxis. Methods Enzymol. 1988, 162, 59-64.
95. Chang, J.; Blazek, E.; Skowtonek, M.; Marinari, L.; Carlson, R. P. The Antiinflammatory Action of Guanabenz is Mediated Through 5-Lipoxygecase and Cyclooxygenase Inhibition. Eur. J. Pharmacol. 1987, 142, 197-205.